Two Treatment Philosophies Shape the Sickle Cell Pipeline: One-Time Gene Therapy Versus Daily Oral Medicine

The sickle cell disease (SCD) pipeline is split by a fundamental strategic question: should treatment aim to correct the disease at its genetic root in a single procedure, or manage it chronically with a pill? Recent survey research shows U.S. hematologists want both. A July 2026 Spherix Global Insights survey of 67 hematologists found enthusiasm for "potentially transformative gene therapies" alongside "more accessible oral disease-modifying options." Here we compare the two leading approaches—FDA-approved gene therapies and oral small molecules—and explain what each could mean for patients.

Introduction to Sickle Cell Disease and Treatment Goals

Why do these two strategies exist side by side? The answer lies in the disease itself. As Vertex Pharmaceuticals explains, SCD stems from a mutation in the HBB gene, which encodes a key component of hemoglobin. The mutation produces abnormal sickle hemoglobin (HbS), making red blood cells rigid so they block small blood vessels and starve tissues of oxygen—a problem that, as Vertex puts it, "can cause problems in every organ in the body."

That biology invites two different goals. A pipeline analysis from DelveInsight notes that hematopoietic stem-cell transplantation and newer gene therapies "can potentially provide a curative or functionally curative approach in appropriately selected patients." In other words, one branch of the pipeline seeks cures. The other accepts lifelong therapy, but in a form far easier to deliver: an oral drug that modifies the disease process day after day.

This is not a comprehensive survey of every SCD drug in development. Instead, we focus on representative examples from each category, based on information available as of late October 2026. Clinical trial status, in particular, changes frequently.

Gene Therapies: Potentially Curative One-Time Treatments

At the most mature end of the pipeline sit two FDA-approved autologous gene therapies: lovo-cel and exa-cel. Because they are autologous, doctors collect a patient's own hematopoietic stem cells, modify them outside the body, and return them as a one-time treatment intended to correct hemoglobin production at its source.

How well do they work in practice? A 2025 clinical comparison published in Experimental Biology and Medicine, authored by Alexis Leonard and Julie Kanter, provides what its authors describe as "the first detailed, side-by-side clinical comparison" of the two approved therapies, integrating efficacy and safety data updated after regulatory approval. The authors analyze differences in trial design, patient eligibility, manufacturing logistics, and clinical outcomes, and report that maturing post-approval data highlight "the durability of therapeutic benefit and emerging patterns of response across diverse patient subgroups."

That last point matters. Durability—whether a one-time intervention keeps working over years—is the central open question for any curative-ambition therapy, and the Leonard and Kanter comparison is one of the first to track it systematically across both approved products.

But approval does not equal easy access. The same analysis flags manufacturing logistics and patient selection as factors that influence real-world implementation. Gene therapy is a hospital-centered, resource-intensive process, which is precisely why accessibility concerns keep oral options in demand.

Small Molecule Inhibitors: Chronic Oral Disease-Modifying Options

The second strategy does not touch the genome at all. It targets the downstream chemistry of the red blood cell. The leading example is mitapivat, developed by Agios Pharmaceuticals. According to Spherix's 2026 research, mitapivat "has surged to the top of hematologists' most desired SCD pipeline therapies," reflecting physician appetite for oral disease-modifying agents.

How does it work? Mitapivat is an allosteric activator of pyruvate kinase (PK), an enzyme central to glycolysis. As Agios describes in its prescribing information, the drug binds the PK enzyme, improving its stability and activity. Increased PK activity is believed to improve ATP production and raise red blood cell energy, which extends the red cell's lifespan, reduces hemolysis, and improves anemia. In sickle cell disease, the strategy is to attack the underlying pathophysiology—energy-starved, fragile red cells—rather than the gene itself.

On development status, a 2026 pipeline analysis from Research and Markets reports that a Phase 3 clinical study sponsored by Novo Nordisk is evaluating a PK activator, etavopivat, for its effectiveness in reducing vaso-occlusive crises, with the trial also assessing organ damage, exercise tolerance, and fatigue. The same analysis covers SCD drug candidates across phases I through IV, tracking product descriptions, trial IDs, drug classes, and modes of administration. Advanced-stage oral candidates like these represent the pipeline's most accessible frontier: a tablet, taken on a schedule, without transplant-level infrastructure.

The trade-off is chronicity. A pill must be taken continuously to keep working, and its benefit accrues through disease modification rather than functional cure. Physicians and patients must weigh treatment burden against the logistical complexity of gene therapy.

Key Therapeutic Approaches in the Sickle Cell Disease Pipeline

The table below categorizes leading candidates by their fundamental scientific strategy. The comparison makes the central distinction visible: where each drug acts on the disease, how it reaches the patient, and how mature its development is. You can use it to see at a glance that the pipeline's diversity is not redundancy—each approach trades off differently on cure potential, logistics, and evidence maturity.

Read the rows together and the strategic contrast is stark. Gene therapy and base editing concentrate enormous intervention into a single event, demanding transplant-grade infrastructure and careful patient selection, as the Leonard and Kanter comparison documents. The small molecule distributes its intervention across years of daily dosing, but requires almost no specialized infrastructure to deliver.

Navigating the Future of Sickle Cell Disease Treatment

Readers should consider the distinct strategic goals of pipeline drugs—curative genetic interventions versus chronic oral management—when evaluating future treatment options for sickle cell disease. Neither category makes the other obsolete; the Spherix survey suggests physicians see them as complementary, with mitapivat topping the wish list even as gene therapy enthusiasm grows.

This article is not medical advice and does not recommend one treatment over another. The development landscape is also moving: the measurable indicators to watch are the approval of new gene editing therapies and the progress of oral disease-modifying agents through late-stage trials into broader clinical use—most immediately, the readout of the Phase 3 PK activator data on vaso-occlusive crises, organ damage, exercise tolerance, and fatigue.

Sources

• As Sickle Cell Innovation Accelerates, Hematologists Signal Demand for a Broader Treatment… — Spherix Global Insights
• Vertex Pharmaceuticals | R&D Pipeline
• Sickle Cell Disease Drugs Pipeline 2026 — Delveinsight
• SEBM | Clinical data comparison for FDA-approved gene therapies in sickle cell disease
• Mechanism of Action — Pyrukynd